Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel ...

Four Hiram College students recently had the opportunity to showcase their original research at regional and statewide ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary ...

GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

Adam Kovalčík figured out how to make an antiviral drug for a fraction of the normal cost, using an alcohol from corn husks.

Country’s pioneering scientific project GenomeIndia will yield the long-term benefit of reducing disease burden, thereby creating a healthier population in the country, said a renowned scientist on ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

Get our top picks of the posters at AACR 2025 and learn more about the method behind them and the techniques used.

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving insulin.

Reports first quarter financial results and highlights clinical momentum. Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers. An upcoming ...

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

Oncolytics Biotech Inc shares T.ONC are trading unchanged at $0.71.